Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

WARREN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) — Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Firm”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech firm, reaffirms his dedication to preserving fairness for shareholders. Amid ongoing discussions about financing approaches within the biotech sector, Dr. Saadi emphasizes his distinct technique, which prioritizes effectivity, asset possession, and a path to income.

“I’m not opposed to the idea of fairness financing, I imagine that preserving fairness is key to preserving a Founder’s imaginative and prescient,” stated Ryan Saadi, Founder and CEO of Tevogen Bio. “From a sensible standpoint, it’s merely not related to us when you think about the next:

• Robust Asset Base: Tevogen Bio believes its property are valued within the billions. This worth will not be mirrored on Tevogen’s stability sheet as internally developed intangible property are usually not permitted to be capitalized as per US GAAP.
• Operational Effectivity: Tevogen Bio’s market cap per worker is roughly 600% larger than the business in accordance to Mr. Damodaran on the Stern College of Enterprise at NYU.
• Self-Sustaining Financing Technique: Whereas Tevogen could safe funds between now and when it begins producing income, it has a number of avenues to achieve this with out promoting fairness.

Concerning the corporate:

• Tevogen’s true worth will grow to be extra well known as consciousness grows.
• The easiest way to acquire TVGN shares is thru employment, as each worker can also be a shareholder.
• Tevogen’s enterprise mannequin challenges conventional biotech financing norms to guarantee long-term sustainability.
• The corporate stays dedicated to making superior immunotherapies accessible and reasonably priced.

About Tevogen Bio

Tevogen Bio is a clinical-stage specialty immunotherapy firm harnessing one of nature’s strongest immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to deal with infectious illness and cancers, aiming to tackle the numerous unmet wants of massive affected person populations. Tevogen Bio management believes that sustainability and business success within the present period of healthcare depend on guaranteeing affected person accessibility via superior science and modern enterprise fashions. Tevogen Bio has reported constructive security information from its proof-of-concept medical trial, and its key mental property property are wholly owned by the corporate, not topic to any third-party licensing agreements. These property embrace three granted patents, 9 pending US and twelve ex-US pending patents, two of that are associated to synthetic intelligence.

Tevogen Bio is pushed by a group of extremely skilled business leaders and distinguished scientists with drug improvement and world product launch expertise. Tevogen Bio’s management believes that accessible personalised therapeutics are the following frontier of medication, and that disruptive enterprise fashions are required to maintain medical innovation.

Ahead Trying Statements

This press launch accommodates sure forward-looking statements, together with with out limitation statements relating to: expectations relating to the healthcare and biopharmaceutical industries; Tevogen’s improvement of, the potential advantages of, and affected person entry to its product candidates for the therapy of infectious illnesses and most cancers; Tevogen’s plans to increase its efforts in synthetic intelligence; Tevogen’s potential to develop further product candidates; Tevogen’s use of funds from the grant; and the potential receipt of further future grants. Ahead-looking statements can typically be recognized by phrases reminiscent of “could,” “might,” “would,” “count on,” “anticipate,” “potential,” “potential,” “purpose,” “alternative,” “mission,” “imagine,” “future,” and comparable phrases and expressions or their opposites. These statements are primarily based on administration’s expectations, assumptions, estimates, projections and beliefs as of the date of this press launch and are topic to a quantity of components that contain recognized and unknown dangers, delays, uncertainties and different components not underneath the corporate’s management which will trigger precise outcomes, efficiency or achievements of the corporate to be materially completely different from the outcomes, efficiency or different expectations expressed or implied by these forward-looking statements.

Components that might trigger precise outcomes, efficiency, or achievements to differ from these expressed or implied by forward-looking statements embrace, however should not restricted to: that Tevogen will want to increase further capital to execute its marketing strategy, which will not be out there on acceptable phrases or in any respect; the impact of the current enterprise mixture with Semper Paratus Acquisition Company (the “Enterprise Mixture”) on Tevogen’s enterprise relationships, working outcomes, and enterprise usually; the end result of any authorized proceedings which may be instituted towards Tevogen; adjustments within the markets during which Tevogen competes, together with with respect to its aggressive panorama, know-how evolution, or regulatory adjustments; adjustments in home and world basic financial circumstances; the danger that Tevogen will not be ready to execute its progress methods or could expertise difficulties in managing its progress and increasing operations; the danger that Tevogen will not be ready to develop and preserve efficient inner controls; prices associated to the Enterprise Mixture and the failure to notice anticipated advantages of the Enterprise Mixture; the failure to obtain Tevogen’s commercialization and improvement plans and establish and notice further alternatives, which can be affected by, amongst different issues, competitors, the power of Tevogen to develop and handle progress economically and rent and retain key workers; the danger that Tevogen could fail to hold tempo with fast technological developments to present new and modern merchandise and companies or make substantial investments in unsuccessful new merchandise and companies; the power to develop, license or purchase new therapeutics; that Tevogen will want to increase further capital to execute its marketing strategy, which will not be out there on acceptable phrases or in any respect; the danger of regulatory lawsuits or proceedings relating to Tevogen’s enterprise; uncertainties inherent within the execution, value, and completion of preclinical research and medical trials; dangers associated to regulatory overview, approval and business improvement; dangers related to mental property safety; Tevogen’s restricted working historical past; and these components mentioned or included by reference in Tevogen’s Annual Report on Kind 10-Okay and subsequent filings with the SEC.

You shouldn’t place undue reliance on forward-looking statements, which communicate solely as of the date they’re made. Tevogen undertakes no obligation to replace any forward-looking statements, besides as required by relevant legislation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com